Cita APA (7a ed.)
Chen, X., Zhang, Y., Mo, S., Ma, H., Lu, Z., Yu, S., & Chen, J. (2023). Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node--Negative, p53--Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma. Archives of Pathology & Laboratory Medicine, 147(4), 465-474.
Cita Chicago Style (17a ed.)
Chen, Xianlong, Yue Zhang, Shengwei Mo, Heng Ma, Zhaohui Lu, Shuangni Yu, y Jie Chen. "Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node--Negative, P53--Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma." Archives of Pathology & Laboratory Medicine 147, no. 4 (2023): 465-474.
Cita MLA (9a ed.)
Chen, Xianlong, et al. "Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node--Negative, P53--Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma." Archives of Pathology & Laboratory Medicine, vol. 147, no. 4, 2023, pp. 465-474.
Precaución: Estas citas no son 100% exactas.